Sairopa is a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system. Cancer treatment was revolutionized by the introduction of so-called immune checkpoint inhibitors, that enhances the immune response against the patient’s own tumor. However only about 30% of cancer patients find benefit from such therapies. It is well accepted that for a productive anti-cancer immune response to happen, all elements of the cancer-immunity cycle need to be functional: tumor-antigen release, antigen-processing, -presentation, T-cell activation and blockade of local immunosuppression in the tumor.
Early 2021 Sairopa acquired, backed by Van Herk Investments, a portfolio of therapeutic antibodies from Chinook Therapeutics. These antibodies were originally developed by BioNovion/Aduro Biotech Europe using the proprietary B-Select antibody platform that was also used to identify pembrolizumab (Keytruda™), BION-1301 and MK-5890 (Guelen et al., 2022).
It is Sairopa’s mission to develop agents that can modulate this cancer-immunity cycle on different points:
ADU-1805, Sairopa’s proprietary anti-SIRPalpha antibody is enhancing tumor cell uptake and presentation to the T cells to induce priming and activation (Voets et al., 2019).
ADU-1604, Sairopa’s proprietary and unique anti-CTLA4 antibody is enhancing T cell priming and activation to raise a higher diversity of tumor cytotoxic immune cells. ADU-1604 is currently being tested in Phase 1 Clinical trials to assess for safety and efficacy in patients suffering from advanced melanoma.
Discovery Programs (undisclosed) that inhibit local immunosuppression in the tumor.
Sairopa programs target distinct parts of the cancer-immunity cycle (adapted from Chen and Mellman, 2013)
Sairopa’s team has a leading reputation in the field of immune oncology and is laser-focused to deliver the therapeutic antibodies towards clinical benefit in cancer patients.
The company is based in Rotterdam, the Netherlands.
Sairopa’s team has a leading reputation in the field of immune oncology and is laser-focused to deliver the therapeutic antibodies towards clinical benefit in cancer patients.
The company is based in Rotterdam, The Netherlands.
Managing Director
Dharminder is Managing Director of Sairopa, he was involved in the foundation and financing of Sairopa. Furthermore, Dharminder is owner and managing director of Exponential B.V. in which capacity he acts as consultant to Van Herk Investments and companies in the Van Herk Investments portfolio. Furthermore, he is CEO and co-founder of SkylineDx a company based in Rotterdam, The Netherlands, and developing diagnostic tests in oncology. Mr. Chahal has built an extensive network in the global life science industry and created a strong track record in supporting successful companies in their journeys. Currently the main investments in the portfolio are Galapagos, Zealand Pharma (Denmark) and BioInvent (Sweden).
As a board member or advisor he has been and still is active for several European companies and funds in the field of life sciences. Mr. Chahal previously held various positions in investment banking and asset management, including Kempen & Co and Robeco. Mr. Chahal obtained a master degree in Business Economics (Erasmus University Rotterdam) and a master degree cum laude in Aerospace Engineering (TU Delft).
Chief Business Officer
Gurvinder is owner and director of Vinco Vita BV. Mr Chahal started his career as a management trainee with the ING Group and has spent 18 years in corporate banking, in several relationship management roles, both in the Netherlands and India for large multinational banks. Mr. Chahal is the Chief Business Officer and Chief Financial Officer of Sairopa BV since foundation of Sairopa BV. Mr. Chahal obtained a master degree in Business Economics (Erasmus University Rotterdam).
Chief Operating Officer
Laura is an experienced clinical professional in Early Oncology and Late Stage Oncology, who started her career in 2006 at an international CRO and has worked at the development of several successful assets in the past 16 years. Due to her experience at various international Pharmaceutical companies (MSD, Acerta Pharma, Astra Zeneca) and Clinical Contract Research Organizations (PPD, ICON) and having worked with and for several partners (Medarex-BMS, IQVIA, Amgen, Pfizer, Lilly Oncology) she is an expert in the strategy and development of clinical trials. With a Master in Health Sciences, specialized in business and health law she has an unique vision on the landscape. Laura is a builder of high performing teams, being a strong advocate for teamwork across companies and international frontiers.
Chief Scientific Officer
After his tenure at Organon, Schering-Plough and MSD, Hans co-founded BioNovion that was acquired by Aduro Inc. in 2015. Until 2019 he served as executive vice-president antibody research and site-head of Aduro Biotech Europe. Later that year he joined AIMM Therapeutics as chief scientific officer and is currently independent consultant in biotechnology. Hans has a strong track record in developing novel therapies in immunology and immune oncology and is (co-)inventor of pembrolizumab (Keytruda), MK-5890 (anti-CD27), BION-1301 (anti-APRIL), ADU-1604 (anti-CTLA4) and ADU-1805 (anti-SIRPalpha). Hans van Eenennaam serves on the Board of Directors of Lygature, Catalym GmBH and ISD Immunotech AsP.
Prof. Eggermont is appointed Chief Scientific Officer of the Princes Máxima Center for pediatric oncology in the Netherlands and serves on the Board of the Comprehensive Cancer Center München, Germany. Prior he was General Director of Gustave Roussy Cancer Campus Grand Paris. Here, he developed Europe’s largest phase 1-2 drug and immunotherapy development program. Prof. Eggermont is Professor Clinical & Translational Immunotherapy, UMC Utrecht, Utrecht University, NL and previously was a Professor of Oncology (Paris-Sud University) and Professor of Oncological Surgery (Erasmus University Rotterdam).
Team Assistant
Deborah has over a decade of experience in the biotech industry supporting teams and management in the day to day business (SkylineDx). Deborah has a strong eye for team dynamics and a pragmatic problem solving mindset. With her Human Resources knowledge and hands on mentality she is invaluable for a strong backbone of the company. She also works as a Personal Assistant to the Chief Executive Officer, acting as a first point of contact for callers, controlling access, managing diaries, the bridge between work floor and management and support with daily time management. In addition she provides assistance for board member meetings and business development
Bioanalytical and safety advisor
Julien Villaudy is co-founder and co-owner of J&S Preclinical Solutions, a consultancy firm specialized in supporting small- to mid-sized companies in their non-clinical package for IND/CTA and NDA/BLA. Julien is a pharmacology and bioanalytic expert with over 14 years of experience in academia and biotechs. Prior he was the head of pharmacology at AIMM Therapeutics were he lead the preclinical activities of their lead compound.
Senior Toxicological Consultant
Sjeng Horbach is co-founder and co-owner of J&S Preclinical Solutions, a consultancy firm specialized in supporting small- to mid-sized companies in their non-clinical package for IND/CTA and NDA/BLA. He is a Toxicology expert with over 35 years of experience. Before starting offering consultancy service, he was employed by CROs, universities and pharmaceutical companies. Most recently, he was the head of the Non-clinical Safety and Toxicology group at Genmab in The Netherlands. Sjeng has a broad experience in preclinical development of pharmaceuticals, both small molecules, biologicals and gene therapy. The projects he has been involved in cover a wide spectrum of therapeutic areas, such as CNS, oncology and fertility.
Head of CMC
Teun van de Laar is Vice President Manufacturing and Supply Chain Management at AM-Pharma, a Dutch Phase 3 biologics pharmaceutical company. Prior to that he was Vice President CMC Technical Operations at Aduro Biotech Inc, with responsibilities in the US and EU. From 2006 to 2016 he was with Merck (MSD) in Biotech Late Stage Process Development and Commercialization. His early career was with Unilever and BAC, in Biotechnology Process Development. Teun holds a Master’s degree in Bioprocess Technology from Wageningen University, completed a PhD in Cell Biology at the University of Utrecht and has over 20 years of experience in biotechnology industry.
Project Manager
As owner of SLC Consultancy and with over 14 years of experience in both clinical and cross-functional project management in biotechnology companies (Amgen, BioMarin, Aduro Biotech Europe, Rainier Therapeutics), Simone is overseeing the cross-functional activities of our clinical programs and supporting the clinical team in the execution of the ongoing clinical trials.
Program Manager CMC
Sara Melief has a background in biomedical sciences. She obtained her PhD in immunology at Leiden University. Over the past 10 years she has been working on the process development and manufacturing of biologics for the treatment of immune-related diseases and in the field of immune-oncology. Sara through employment at 3D-PharmXchange is Program manager CMC and manages projects with both internal as well as external collaborators.
Chief Legal Counsel
Blaine brings over 25 years of experience leading oncology and vaccine companies in product development, partnering and commercialization, protection of IP portfolios, and the management of businesses operations. From 2015-2020, Blaine was the Chief Administrative Officer and Chief Legal Officer of Aduro Biotech. Prior to that he was a corporate and intellectual property partner at Arnold & Porter, LLP and Sheppard Mullin LLP. Blaine has a J.D. from New York University School of Law and a B.A from Oral Roberts University. He also attended Princeton Seminary.
Preclinical and Pharmacology consultant
Joost Kreijtz is Chief Development Officer at Trained Therapeutix Discovery, a preclinical stage biotech company. Prior to that he was Chief of Staff at Aduro Biotech Europe, working with project teams in the Netherlands and US to drive Aduro’s therapeutic antibody programs forward. During his time at Aduro, Joost was responsible for the preclinical development of ADU-1604 (co-inventor), late-stage preclinical development of ADU-1805 and the preclinical oversight for the BION-1301 program (Chinook Therapeutics). Joost started his career at the Viroscience Lab at the Erasmus Medical Center Rotterdam where he completed a PhD in immunovirology and brought a viral vector-based vaccine against highly pathogenic avian influenza from bench to bedside in the form of a Phase I/IIa clinical trial.
